Come up with a name for your new list and we'll add to it:
Blueprint Medicines raised a round of funding on April 11, 2011. Investors include
Third Rock Ventures.
Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world…